Yazarlar (6) |
![]() Ankara Üniversitesi, Türkiye |
![]() Kırşehir Ahi Evran Üniversitesi, Türkiye |
![]() |
![]() Ankara Yıldırım Beyazıt Üniversitesi, Türkiye |
![]() |
![]() |
Özet |
This study aimed to determine the effects of nine OPRM1, OPRD1 and OPRK1 polymorphisms on plasma BUP and norbuprenorphine (norBUP) concentrations and various treatment responses in a sample of 122 patients receiving BUP/naloxone. Plasma concentrations of BUP and norBUP were detected by LC-MS/MS. PCR-RFLP method was used to genotype polymorphisms. OPRD1 rs569356 GG had significantly lower plasma norBUP concentration (p = 0.018), dose-(p = 0.049) and dose/kg-normalized norBUP values (p = 0.036) compared with AA. Craving and withdrawal symptoms were significantly higher in OPRD1 rs569356 AG+GG relative to AA. There was a statistically significant difference between the OPRD1 rs678849 genotypes in the intensity of anxiety (13.5 for CT+TT and 7.5 for TT). OPRM1 rs648893 TT (18.8 +/- 10.8) was significantly different to CC+CT (14.82 +/- 11.3; p = 0.049) in view of the intensity of depression. This current study provides the first data on a prominent effect of the OPRD1 rs569356 variation on BUP pharmacology due to its metabolite norBUP. |
Anahtar Kelimeler |
Opioid use disorder | Norbuprenorphine | Opioid receptors | Pharmacodynamics | Craving | Withdrawal |
Makale Türü | Özgün Makale |
Makale Alt Türü | SSCI, AHCI, SCI, SCI-Exp dergilerinde yayımlanan tam makale |
Dergi Adı | ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY |
Dergi ISSN | 1382-6689 |
Dergi Tarandığı Indeksler | SCI-Expanded |
Dergi Grubu | Q1 |
Makale Dili | Türkçe |
Basım Tarihi | 06-2023 |
Cilt No | 100 |
Sayfalar | 104143 / 0 |
Doi Numarası | 10.1016/j.etap.2023.104143 |
Makale Linki | http://dx.doi.org/10.1016/j.etap.2023.104143 |